Immupharma (IMM)


ImmuPharma gives update on cancer programme

ImmuPharma has issued an update on its lead cancer programme IPP-204106. The company says that as announced in September last year, it commenced dosing in cancer patients with the next generation of the 'polyplexed Nucant'.

Three hospitals are conducting these trials designed to assess safety and dosing levels in Europe including the prestigious Institute Jules Bordet, an Integrated Multidisciplinary Centre which is the only autonomous hospital in Belgium totally dedicated to cancer.

The trial is progressing according to protocol and its objective is to identify the optimal dose for treating patients. The oncologists involved in the study are leading the decisions on the number of patients and the dosing regimen.

Patients that are being enrolled in this trial are in a serious condition, suffering from a range of cancers, all have metastasis (tumour spreading) and have failed their previous treatment.

This trial will be followed by a phase II efficacy study designed to treat various cancers, in approximately 30 patients, to identify appropriate biomarkers.

The company says its further intention is to conduct more focused follow-up studies on patients with glioblastoma (brain tumour), metastatic melanoma, and pancreatic cancer where nucleolin plays a key role and who are showing the appropriate biomarkers.